4 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
A residue-resolved prioritization platform for covalent cancer drug discovery. CanProTarget integrates cancer gene dependencies, small-molecule covalent ligand engagement measured by chemoproteomics, and base-editing evidence for individual cysteines, keeping each layer at the resolution it is measured at.
A residue-resolved prioritization platform for covalent cancer drug discovery. CanProTarget integrates cancer gene dependencies, small-molecule covalent ligand engagement measured by chemoproteomics, and base-editing evidence for individual cysteines, keeping each layer at the resolution it is measured at.
A residue-resolved prioritization platform for covalent cancer drug discovery. CanProTarget integrates cancer gene dependencies, small-molecule covalent ligand engagement measured by chemoproteomics, and base-editing evidence for individual cysteines, keeping each layer at the resolution it is measured at.
A residue-resolved prioritization platform for covalent cancer drug discovery. CanProTarget integrates cancer gene dependencies, small-molecule covalent ligand engagement measured by chemoproteomics, and base-editing evidence for individual cysteines, keeping each layer at the resolution it is measured at.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
